ScreenerHero
ONWDOnward Medical N.V.
EBR · BE · Healthcare · Biotechnology · onwd.com
2.370EUR+0.21%Mkt Cap: 179.11M $P/E: —

Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with spinal cord injury (SCI) in the United States, Europe, and internationally. The compa…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap179.11M $
Enterprise Value84.80M $
Revenue (TTM)5.88M $
Gross Profit2.98M $
Net Income (TTM)-45.42M $
Revenue/Share0.1261 USD
Last Price2.370 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees137
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINNL0015000HT4
Valuation
P/E (Trailing)—
P/E (Forward)-3.68
PEG—
EV/EBITDA-1.93
EV/Revenue14.41
P/S30.37
P/B2.39
EPS (TTM)-0.90
EPS (Forward)-0.64
52W Range
2.2703% of range5.770
52W High5.770 EUR
52W Low2.270 EUR
Profitability
Gross Margin72.51%
Oper. Margin-494.49%
EBITDA Margin0.00%
Profit Margin-1105.48%
ROE-75.54%
ROA-49.42%
Growth
Revenue Growth176.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-42.46M $
CapEx (TTM)469.57K $
FCF Margin-439.37%
FCF Yield-14.44%
Net Debt-59.18M $
Net Debt/EBITDA1.35
Balance Sheet
Debt/Equity0.25
Current Ratio6.67
Quick Ratio6.40
Book Value/Sh0.9880 EUR
Cash/Share1.216 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)9.240 EUR
Upside (mean)+289.9%
Target Range8.100 EUR – 11.00 EUR
€8.100+289.9% to mean€11.00
# Analysts5
Ownership
Shares Out.69.53M
Float43.98M
Insiders28.48%
Institutions23.58%
Technical
SMA 502.494 (-5.0%)
SMA 2003.405 (-30.4%)
Beta0.85
S&P 52W Chg18.16%
Avg Vol (30d)88.57K
Avg Vol (10d)117.57K
Technical Indicators
RSI (14)43.9
MACD-0.0404
MACD Signal-0.0466
MACD Hist.+0.0062
BB Upper2.452 EUR
BB Middle2.381 EUR
BB Lower2.309 EUR
BB Width6.01%
ATR (14)0.0807 EUR
Vol Ratio (20d)0.22x